S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
Log in
(Ad)
Located just 25 miles from Cleveland... is a supergreenhouse unlike anything we've ever seen. Listed at over 1.4 million sq ft, (the size of 9 full-sized Costco warehouses), this marijuana grow house is capable of producing over 341,000 pounds of weed/year! And very soon it will come online and could turn a tiny 60-cent pot company into the dominator in the white-hot weed market.

NYSE:ARA - American Renal Associates Stock Price, Forecast & News

$9.66
-0.18 (-1.83 %)
(As of 01/20/2020 11:18 AM ET)
Today's Range
$9.65
Now: $9.66
$10.04
50-Day Range
$8.80
MA: $9.70
$10.42
52-Week Range
$5.48
Now: $9.66
$14.10
Volume62,744 shs
Average Volume71,929 shs
Market Capitalization$315.01 million
P/E RatioN/A
Dividend YieldN/A
Beta2.16
American Renal Associates Holdings, Inc operates as a dialysis services provider in the United States. It operates dialysis clinics focusing on joint venture partnerships with physicians. The company offers kidney dialysis services to patients suffering from chronic kidney failure or end stage renal disease. As of June 30, 2018, it owned and operated 233 dialysis clinics in partnership with 400 nephrologist partners treating approximately 16,000 patients in 26 states and the District of Columbia. Read More…

Industry, Sector and Symbol

Industry Miscellaneous health & allied services, not elsewhere classified
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone978-922-3080

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$805.78 million
Cash Flow$1.98 per share
Book Value$3.38 per share

Profitability

Net Income$-28,770,000.00

Miscellaneous

Employees4,932
Market Cap$315.01 million
Next Earnings Date2/4/2020 (Estimated)
OptionableOptionable

Receive ARA News and Ratings via Email

Sign-up to receive the latest news and ratings for ARA and its competitors with MarketBeat's FREE daily newsletter.


American Renal Associates (NYSE:ARA) Frequently Asked Questions

What is American Renal Associates' stock symbol?

American Renal Associates trades on the New York Stock Exchange (NYSE) under the ticker symbol "ARA."

How were American Renal Associates' earnings last quarter?

American Renal Associates Holdings Inc (NYSE:ARA) announced its quarterly earnings results on Tuesday, November, 5th. The company reported $0.33 EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.04) by $0.37. The business earned $211.43 million during the quarter, compared to analysts' expectations of $215.06 million. American Renal Associates had a positive return on equity of 23.16% and a negative net margin of 1.75%. View American Renal Associates' Earnings History.

When is American Renal Associates' next earnings date?

American Renal Associates is scheduled to release their next quarterly earnings announcement on Tuesday, February 4th 2020. View Earnings Estimates for American Renal Associates.

What price target have analysts set for ARA?

5 brokers have issued 12 month price targets for American Renal Associates' stock. Their forecasts range from $7.00 to $12.00. On average, they anticipate American Renal Associates' share price to reach $10.00 in the next twelve months. This suggests a possible upside of 3.5% from the stock's current price. View Analyst Price Targets for American Renal Associates.

What is the consensus analysts' recommendation for American Renal Associates?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for American Renal Associates in the last year. There are currently 5 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for American Renal Associates.

Has American Renal Associates been receiving favorable news coverage?

News stories about ARA stock have been trending positive recently, InfoTrie Sentiment Analysis reports. The research firm scores the sentiment of press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. American Renal Associates earned a coverage optimism score of 3.0 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for American Renal Associates.

Who are some of American Renal Associates' key competitors?

What other stocks do shareholders of American Renal Associates own?

Based on aggregate information from My MarketBeat watchlists, some companies that other American Renal Associates investors own include Akorn (AKRX), Collegium Pharmaceutical (COLL), Exelixis (EXEL), Amicus Therapeutics (FOLD), KemPharm (KMPH), Madrigal Pharmaceuticals (MDGL), Mylan (MYL), Pattern Energy Group (PEGI), Catalyst Pharmaceuticals (CPRX) and Fate Therapeutics (FATE).

Who are American Renal Associates' key executives?

American Renal Associates' management team includes the folowing people:
  • Mr. Joseph A. Carlucci, Co-Founder, CEO & Chairman (Age 65)
  • Mr. Syed T. Kamal, Founder, Pres & Director (Age 66)
  • Mr. Mark C. Herbers, Interim CFO & Interim Chief Accounting Officer (Age 64)
  • Dr. Don E. Williamson, Exec. VP & COO (Age 56)
  • Mr. Richard Pacheco CFE, AVA, MBA, VP of Admin.

When did American Renal Associates IPO?

(ARA) raised $161 million in an initial public offering (IPO) on Thursday, April 21st 2016. The company issued 7,500,000 shares at $20.00-$23.00 per share. BofA Merrill Lynch, Barclays and Goldman Sachs acted as the underwriters for the IPO and Wells Fargo Securities, SunTrust Robinson Humphrey and Leerink Partners were co-managers.

Who are American Renal Associates' major shareholders?

American Renal Associates' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Private Asset Management Inc. (0.09%). View Institutional Ownership Trends for American Renal Associates.

Which major investors are buying American Renal Associates stock?

ARA stock was purchased by a variety of institutional investors in the last quarter, including Private Asset Management Inc.. View Insider Buying and Selling for American Renal Associates.

How do I buy shares of American Renal Associates?

Shares of ARA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is American Renal Associates' stock price today?

One share of ARA stock can currently be purchased for approximately $9.66.

How big of a company is American Renal Associates?

American Renal Associates has a market capitalization of $315.01 million and generates $805.78 million in revenue each year. American Renal Associates employs 4,932 workers across the globe.View Additional Information About American Renal Associates.

What is American Renal Associates' official website?

The official website for American Renal Associates is http://www.americanrenal.com/.

How can I contact American Renal Associates?

American Renal Associates' mailing address is 500 CUMMINGS CENTER SUITE 6550, BEVERLY MA, 01915. The company can be reached via phone at 978-922-3080 or via email at [email protected]


MarketBeat Community Rating for American Renal Associates (NYSE ARA)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  197 (Vote Outperform)
Underperform Votes:  227 (Vote Underperform)
Total Votes:  424
MarketBeat's community ratings are surveys of what our community members think about American Renal Associates and other stocks. Vote "Outperform" if you believe ARA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/20/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel